H1 2024 revenue and net profit declined year-over-year due to high base effects and policy headwinds, but cardiovascular device and overseas segments showed growth. The company advanced its innovation pipeline and expects pharmaceutical sector stabilization after channel adjustments.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.